Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 168

1.

Three-Tesla MRI does not improve the diagnosis of multiple sclerosis: A multicenter study.

Hagens MHJ, Burggraaff J, Kilsdonk ID, de Vos ML, Cawley N, Sbardella E, Andelova M, Amann M, Lieb JM, Pantano P, Lissenberg-Witte BI, Killestein J, Oreja-Guevara C, Ciccarelli O, Gasperini C, Lukas C, Wattjes MP, Barkhof F; MAGNIMS Study Group.

Neurology. 2018 Jul 17;91(3):e249-e257. doi: 10.1212/WNL.0000000000005825. Epub 2018 Jun 20.

PMID:
29925550
2.

[Diagnosis of multiple sclerosis: revision of the McDonald criteria 2017].

Aktas O, Wattjes MP, Stangel M, Hartung HP.

Nervenarzt. 2018 Jun 6. doi: 10.1007/s00115-018-0550-0. [Epub ahead of print] Review. German.

PMID:
29876600
3.

The course of apathy in late-life depression treated with electroconvulsive therapy; a prospective cohort study.

Carlier A, van Exel E, Dols A, Bouckaert F, Sienaert P, Ten Kate M, Wattjes MP, Vandenbulcke M, Stek ML, Rhebergen D.

Int J Geriatr Psychiatry. 2018 May 30. doi: 10.1002/gps.4917. [Epub ahead of print]

PMID:
29851173
4.

Imaging Patterns of Muscle Atrophy.

Weber MA, Wolf M, Wattjes MP.

Semin Musculoskelet Radiol. 2018 Jul;22(3):299-306. doi: 10.1055/s-0038-1641574. Epub 2018 May 23.

PMID:
29791958
5.

Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.

Wijburg MT, Kleerekooper I, Lissenberg-Witte BI, de Vos M, Warnke C, Uitdehaag BMJ, Barkhof F, Killestein J, Wattjes MP.

JAMA Neurol. 2018 Jul 1;75(7):827-833. doi: 10.1001/jamaneurol.2018.0094.

PMID:
29532061
6.

Disease activity following pregnancy-related discontinuation of natalizumab in MS.

Kleerekooper I, van Kempen ZLE, Leurs CE, Dekker I, Rispens T, Lissenberg-Witte BI, van Munster CEP, de Jong BA, van Oosten BW, Uitdehaag BMJ, Wattjes MP, Killestein J.

Neurol Neuroimmunol Neuroinflamm. 2017 Dec 5;5(1):e424. doi: 10.1212/NXI.0000000000000424. eCollection 2018 Jan.

7.

Impact of 3 Tesla MRI on interobserver agreement in clinically isolated syndrome: A MAGNIMS multicentre study.

Hagens MH, Burggraaff J, Kilsdonk ID, Ruggieri S, Collorone S, Cortese R, Cawley N, Sbardella E, Andelova M, Amann M, Lieb JM, Pantano P, Lissenberg-Witte BI, Killestein J, Oreja-Guevara C, Wuerfel J, Ciccarelli O, Gasperini C, Lukas C, Rovira A, Barkhof F, Wattjes MP; MAGNIMS Study Group.

Mult Scler. 2018 Jan 1:1352458517751647. doi: 10.1177/1352458517751647. [Epub ahead of print]

PMID:
29327668
8.

Gray matter networks and cognitive impairment in multiple sclerosis.

Rimkus CM, Schoonheim MM, Steenwijk MD, Vrenken H, Eijlers AJ, Killestein J, Wattjes MP, Leite CC, Barkhof F, Tijms BM.

Mult Scler. 2018 Jan 1:1352458517751650. doi: 10.1177/1352458517751650. [Epub ahead of print]

PMID:
29320933
9.

Inflammatory natalizumab-associated PML: baseline characteristics, lesion evolution and relation with PML-IRIS.

Wattjes MP, Wijburg MT, van Eijk J, Frequin S, Uitdehaag BMJ, Barkhof F, Warnke C, Killestein J; Dutch-Belgian Natalizumab-Associated PML Study Group.

J Neurol Neurosurg Psychiatry. 2018 May;89(5):535-541. doi: 10.1136/jnnp-2017-316886. Epub 2017 Nov 15.

PMID:
29142146
10.

Fulminant intramedullary spinal cord sarcoidosis.

Graf J, Ringelstein M, Aktas O, Wattjes MP, Hartung HP.

Mult Scler Relat Disord. 2017 Nov;18:47-48. doi: 10.1016/j.msard.2017.09.010. Epub 2017 Sep 13.

PMID:
29141820
11.

Asymptomatic spinal cord lesions do not predict the time to disability in patients with early multiple sclerosis.

Dekker I, Sombekke MH, Witte BI, Geurts JJ, Barkhof F, Uitdehaag BM, Killestein J, Wattjes MP.

Mult Scler. 2018 Apr;24(4):481-490. doi: 10.1177/1352458517736147. Epub 2017 Nov 6.

12.

Neuromyelitis optica spectrum disorder mimicking multiple sclerosis.

van Rooij LC, Wattjes MP, de Jong BA, van Oosten BW.

Mult Scler Relat Disord. 2017 Oct;17:54-56. doi: 10.1016/j.msard.2017.06.009. Epub 2017 Jun 29.

PMID:
29055475
13.

Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project.

van Maurik IS, Zwan MD, Tijms BM, Bouwman FH, Teunissen CE, Scheltens P, Wattjes MP, Barkhof F, Berkhof J, van der Flier WM; Alzheimer’s Disease Neuroimaging Initiative.

JAMA Neurol. 2017 Dec 1;74(12):1481-1491. doi: 10.1001/jamaneurol.2017.2712.

PMID:
29049480
14.

[Imaging of primary muscular diseases : What do neurologists expect from radiologists?]

Wattjes MP, Fischmann A, Fischer D.

Radiologe. 2017 Dec;57(12):1005-1011. doi: 10.1007/s00117-017-0309-9. Review. German.

PMID:
28986620
15.

The value of subtraction MRI in detection of amyloid-related imaging abnormalities with oedema or effusion in Alzheimer's patients: An interobserver study.

Martens RM, Bechten A, Ingala S, van Schijndel RA, Machado VB, de Jong MC, Sanchez E, Purcell D, Arrighi MH, Brashear RH, Wattjes MP, Barkhof F.

Eur Radiol. 2018 Mar;28(3):1215-1226. doi: 10.1007/s00330-017-5022-6. Epub 2017 Sep 27.

16.

Performance of five research-domain automated WM lesion segmentation methods in a multi-center MS study.

de Sitter A, Steenwijk MD, Ruet A, Versteeg A, Liu Y, van Schijndel RA, Pouwels PJW, Kilsdonk ID, Cover KS, van Dijk BW, Ropele S, Rocca MA, Yiannakas M, Wattjes MP, Damangir S, Frisoni GB, Sastre-Garriga J, Rovira A, Enzinger C, Filippi M, Frederiksen J, Ciccarelli O, Kappos L, Barkhof F, Vrenken H; MAGNIMS study group and for neuGRID.

Neuroimage. 2017 Dec;163:106-114. doi: 10.1016/j.neuroimage.2017.09.011. Epub 2017 Sep 9.

PMID:
28899746
17.

Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients.

Leurs CE, van Kempen ZL, Dekker I, Balk LJ, Wattjes MP, Rispens T, Uitdehaag BM, Killestein J.

Mult Scler. 2017 Aug 1:1352458517726381. doi: 10.1177/1352458517726381. [Epub ahead of print]

PMID:
28823223
18.

Erratum to: Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases.

Gieselbach RJ, Muller-Hansma AH, Wijburg MT, de Bruin-Weller MS, van Oosten BW, Nieuwkamp DJ, Coenjaerts FE, Wattjes MP, Murk JL.

J Neurol. 2017 Aug;264(8):1833-1836. doi: 10.1007/s00415-017-8557-1. No abstract available.

PMID:
28711999
19.

John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients.

van Kempen ZLE, Leurs CE, de Vries A, Vennegoor A, Rispens T, Wattjes MP, Killestein J.

Eur J Neurol. 2017 Sep;24(9):1196-1199. doi: 10.1111/ene.13355. Epub 2017 Jul 14.

PMID:
28707781
20.

Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases.

Gieselbach RJ, Muller-Hansma AH, Wijburg MT, de Bruin-Weller MS, van Oosten BW, Nieuwkamp DJ, Coenjaerts FE, Wattjes MP, Murk JL.

J Neurol. 2017 Jun;264(6):1155-1164. doi: 10.1007/s00415-017-8509-9. Epub 2017 May 23. Review. Erratum in: J Neurol. 2017 Jul 15;:.

PMID:
28536921
21.

MRI Visual Ratings of Brain Atrophy and White Matter Hyperintensities across the Spectrum of Cognitive Decline Are Differently Affected by Age and Diagnosis.

Rhodius-Meester HFM, Benedictus MR, Wattjes MP, Barkhof F, Scheltens P, Muller M, van der Flier WM.

Front Aging Neurosci. 2017 May 9;9:117. doi: 10.3389/fnagi.2017.00117. eCollection 2017.

22.

Application of the CSF JCV antibody index to early natalizumab-associated progressive multifocal leukoencephalopathy.

Warnke C, Wijburg MT, Hartung HP, Killestein J, Adams O, Wattjes MP.

J Neurol Neurosurg Psychiatry. 2017 Dec;88(12):1092-1094. doi: 10.1136/jnnp-2016-315298. Epub 2017 May 10. No abstract available.

PMID:
28490505
23.

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing.

van Kempen ZL, Leurs CE, Witte BI, de Vries A, Wattjes MP, Rispens T, Killestein J.

Mult Scler. 2018 May;24(6):805-810. doi: 10.1177/1352458517708464. Epub 2017 May 9.

24.

In-vivo imaging of meningeal inflammation in multiple sclerosis: Presence of evidence or evidence of presence?

Kilsdonk ID, Schoonheim M, Wattjes MP.

Mult Scler. 2017 Jul;23(8):1169-1171. doi: 10.1177/1352458517704924. Epub 2017 Apr 18. No abstract available.

25.

Brain and Spinal Cord MR Imaging Features in Multiple Sclerosis and Variants.

Dekker I, Wattjes MP.

Neuroimaging Clin N Am. 2017 May;27(2):205-227. doi: 10.1016/j.nic.2016.12.002. Review.

PMID:
28391782
26.

Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications.

Igra MS, Paling D, Wattjes MP, Connolly DJA, Hoggard N.

Br J Radiol. 2017 Jun;90(1074):20160721. doi: 10.1259/bjr.20160721. Epub 2017 Apr 26. Review.

27.

Acute influenza virus-associated encephalitis and encephalopathy in adults: a challenging diagnosis.

Meijer WJ, Linn FH, Wensing AM, Leavis HL, van Riel D, GeurtsvanKessel CH, Wattjes MP, Murk JL.

JMM Case Rep. 2016 Dec 19;3(6):e005076. doi: 10.1099/jmmcr.0.005076. eCollection 2016 Dec.

28.

Progressive multifocal leukoencephalopathy and black fungus in a patient with rheumatoid arthritis without severe lymphocytopenia.

de Regt MJ, Murk JL, Schneider-Hohendorf T, Wattjes MP, Hoepelman AI, Arends JE.

JMM Case Rep. 2016 Aug 30;3(4):e005053. doi: 10.1099/jmmcr.0.005053. eCollection 2016 Aug.

29.

High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - Commentary.

Wattjes MP, Warnke C.

Mult Scler. 2017 May;23(6):770-771. doi: 10.1177/1352458516685170. Epub 2017 Mar 1. No abstract available.

PMID:
28287040
30.

Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design.

de Wilde A, van Maurik IS, Kunneman M, Bouwman F, Zwan M, Willemse EA, Biessels GJ, Minkman M, Pel R, Schoonenboom NS, Smets EM, Wattjes MP, Barkhof F, Stephens A, van Lier EJ, Batrla-Utermann R, Scheltens P, Teunissen CE, van Berckel BN, van der Flier WM.

Alzheimers Dement (Amst). 2017 Jan 23;6:143-151. doi: 10.1016/j.dadm.2017.01.003. eCollection 2017.

31.

Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations.

van Kempen ZL, Leurs CE, Vennegoor A, Wattjes MP, Rispens T, Uitdehaag BM, Killestein J.

Mult Scler. 2017 Jun;23(7):995-999. doi: 10.1177/1352458516684023. Epub 2016 Dec 13.

PMID:
28112019
32.

Validation of an MRI Rating Scale for Amyloid-Related Imaging Abnormalities.

Bechten A, Wattjes MP, Purcell DD, Aliaga ES, Daams M, Brashear HR, Arrighi HM, Barkhof F.

J Neuroimaging. 2017 May;27(3):318-325. doi: 10.1111/jon.12422. Epub 2017 Jan 19.

PMID:
28102639
33.

[Progressive multifocal leukoencephalopathy].

Warnke C, Wattjes MP, Adams O, Hartung HP, Martin R, Weber T, Stangel M.

Nervenarzt. 2016 Dec;87(12):1300-1304. Review. German.

PMID:
27730274
34.

MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance.

Wijburg MT, Witte BI, Vennegoor A, Roosendaal SD, Sanchez E, Liu Y, Martins Jarnalo CO, Uitdehaag BM, Barkhof F, Killestein J, Wattjes MP.

J Neurol Neurosurg Psychiatry. 2016 Oct;87(10):1138-45. doi: 10.1136/jnnp-2016-313772. Epub 2016 Aug 16.

PMID:
27530808
35.

Recent developments in muscle imaging of neuromuscular disorders.

Fischer D, Bonati U, Wattjes MP.

Curr Opin Neurol. 2016 Oct;29(5):614-20. doi: 10.1097/WCO.0000000000000364. Review.

PMID:
27427989
36.

Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases.

Maas RP, Muller-Hansma AH, Esselink RA, Murk JL, Warnke C, Killestein J, Wattjes MP.

J Neurol. 2016 Oct;263(10):2004-21. doi: 10.1007/s00415-016-8217-x. Epub 2016 Jul 11.

37.

Diagnostic Accuracy of MRI and Additional [18F]FDG-PET for Behavioral Variant Frontotemporal Dementia in Patients with Late Onset Behavioral Changes.

Vijverberg EG, Wattjes MP, Dols A, Krudop WA, Möller C, Peters A, Kerssens CJ, Gossink F, Prins ND, Stek ML, Scheltens P, van Berckel BN, Barkhof F, Pijnenburg YA.

J Alzheimers Dis. 2016 Jun 30;53(4):1287-97. doi: 10.3233/JAD-160285.

PMID:
27372646
38.

Elevated CSF neurofilament proteins predict brain atrophy: A 15-year follow-up study.

Petzold A, Steenwijk MD, Eikelenboom JM, Wattjes MP, Uitdehaag BM.

Mult Scler. 2016 Aug;22(9):1154-62. doi: 10.1177/1352458516645206. Epub 2016 May 11.

PMID:
27207456
39.

Diagnostic Accuracy of the Frontotemporal Dementia Consensus Criteria in the Late-Onset Frontal Lobe Syndrome.

Vijverberg EG, Dols A, Krudop WA, Peters A, Kerssens CJ, van Berckel BN, Wattjes MP, Barkhof F, Gossink F, Prins ND, Stek ML, Scheltens P, Pijnenburg YA.

Dement Geriatr Cogn Disord. 2016;41(3-4):210-9. doi: 10.1159/000444849. Epub 2016 May 5.

40.

Power estimation for non-standardized multisite studies.

Keshavan A, Paul F, Beyer MK, Zhu AH, Papinutto N, Shinohara RT, Stern W, Amann M, Bakshi R, Bischof A, Carriero A, Comabella M, Crane JC, D'Alfonso S, Demaerel P, Dubois B, Filippi M, Fleischer V, Fontaine B, Gaetano L, Goris A, Graetz C, Gröger A, Groppa S, Hafler DA, Harbo HF, Hemmer B, Jordan K, Kappos L, Kirkish G, Llufriu S, Magon S, Martinelli-Boneschi F, McCauley JL, Montalban X, Mühlau M, Pelletier D, Pattany PM, Pericak-Vance M, Cournu-Rebeix I, Rocca MA, Rovira A, Schlaeger R, Saiz A, Sprenger T, Stecco A, Uitdehaag BMJ, Villoslada P, Wattjes MP, Weiner H, Wuerfel J, Zimmer C, Zipp F; International Multiple Sclerosis Genetics Consortium. Electronic address: AIVINSON@PARTNERS.ORG, Hauser SL, Oksenberg JR, Henry RG.

Neuroimage. 2016 Jul 1;134:281-294. doi: 10.1016/j.neuroimage.2016.03.051. Epub 2016 Apr 1.

41.

High cumulative JC virus seroconversion rate during long-term use of natalizumab.

Vennegoor A, van Rossum JA, Leurs C, Wattjes MP, Rispens T, Murk JL, Uitdehaag BM, Killestein J.

Eur J Neurol. 2016 Jun;23(6):1079-85. doi: 10.1111/ene.12988. Epub 2016 Mar 27.

PMID:
27018481
42.

Muscle imaging in inherited and acquired muscle diseases.

Ten Dam L, van der Kooi AJ, Verhamme C, Wattjes MP, de Visser M.

Eur J Neurol. 2016 Apr;23(4):688-703. doi: 10.1111/ene.12984. Review.

PMID:
27000978
43.

Increased cortical grey matter lesion detection in multiple sclerosis with 7 T MRI: a post-mortem verification study.

Kilsdonk ID, Jonkman LE, Klaver R, van Veluw SJ, Zwanenburg JJ, Kuijer JP, Pouwels PJ, Twisk JW, Wattjes MP, Luijten PR, Barkhof F, Geurts JJ.

Brain. 2016 May;139(Pt 5):1472-81. doi: 10.1093/brain/aww037. Epub 2016 Mar 8.

PMID:
26956422
44.

Heterogeneous Language Profiles in Patients with Primary Progressive Aphasia due to Alzheimer's Disease.

Louwersheimer E, Keulen MA, Steenwijk MD, Wattjes MP, Jiskoot LC, Vrenken H, Teunissen CE, van Berckel BN, van der Flier WM, Scheltens P, van Swieten JC, Pijnenburg YA.

J Alzheimers Dis. 2016;51(2):581-90. doi: 10.3233/JAD-150812.

PMID:
26890751
45.

Concomitant granule cell neuronopathy in patients with natalizumab-associated PML.

Wijburg MT, Siepman D, van Eijk JJ, Killestein J, Wattjes MP.

J Neurol. 2016 Apr;263(4):649-56. doi: 10.1007/s00415-015-8001-3. Epub 2016 Jan 25.

46.

Whole brain functional connectivity in clinically isolated syndrome without conventional brain MRI lesions.

Liu Y, Dai Z, Duan Y, Huang J, Ren Z, Liu Z, Dong H, Shu N, Vrenken H, Wattjes MP, Barkhof F, He Y, Li K.

Eur Radiol. 2016 Sep;26(9):2982-91. doi: 10.1007/s00330-015-4147-8. Epub 2015 Dec 29.

PMID:
26714968
47.

Multicenter Validation of Mean Upper Cervical Cord Area Measurements from Head 3D T1-Weighted MR Imaging in Patients with Multiple Sclerosis.

Liu Y, Lukas C, Steenwijk MD, Daams M, Versteeg A, Duan Y, Li K, Weiler F, Hahn HK, Wattjes MP, Barkhof F, Vrenken H.

AJNR Am J Neuroradiol. 2016 Apr;37(4):749-54. doi: 10.3174/ajnr.A4635. Epub 2015 Dec 10.

48.

Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients.

Wattjes MP, Wijburg MT, Vennegoor A, Witte BI, Roosendaal SD, Sanchez E, Liu Y, Martins Jarnalo CO, Richert ND, Uitdehaag BM, Barkhof F, Killestein J.

Mult Scler. 2016 Aug;22(9):1174-83. doi: 10.1177/1352458515615225. Epub 2015 Nov 12.

PMID:
26564995
49.

[Diagnostic imaging in dementia: use of imaging modalities in Dutch memory clinics].

Gardeniers M, Wattjes MP, Meulen EF, Barkhof F, Bakker J.

Tijdschr Gerontol Geriatr. 2016 Feb;47(1):2-8. doi: 10.1007/s12439-015-0154-0. Dutch.

PMID:
26525706
50.

Guidelines on PML risk stratification and diagnosis in patients with MS treated with natalizumab: so far so good?

Wattjes MP, Warnke C.

J Neurol Neurosurg Psychiatry. 2016 Feb;87(2):115. doi: 10.1136/jnnp-2015-311386. Epub 2015 Oct 22. No abstract available.

PMID:
26492928

Supplemental Content

Loading ...
Support Center